The National Cancer Institute defines immunotherapy as
A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases. Some types of immunotherapy only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG), and some monoclonal antibodies. (NCI)
Fight Colorectal Cancer is committed to immunotherapy research.
Writing a Blueprint
Gordon Cole was a friend to many at Fight CRC. He helped found our organization and served on our board. Many people knew and loved Gordon. His passion for research and hope in immunotherapy was contagious.
After he passed in 2015, his family gave a legacy gift to Fight Colorectal Cancer. We used the funds to convene over 20 global experts in colorectal cancer immunotherapy in partnership with the Cancer Research Institute (CRI). Together we hosted a meeting in New York City where researchers began to discuss how to move the science forward. This had never happened before.
Gordon made it possible.
Out of that meeting, the Immunotherapy (IO) Work Group was formed. The IO Work Group consists of multidisciplinary experts in the fields of CRC and IO from around the world. The group is committed to moving IO forward by synthesizing research and identifying gaps in translational and clinical research, and following the path of the science and advising research. Fight CRC works with this group and engages them to discuss priorities for projects and funding. With the group’s input, grants will be given to advance immunotherapy science.Meet the Immunotherapy Work Group
A Blueprint to Advance Colorectal Cancer Immunotherapy
The IO Work Group created a plan for follow-up discussions after their initial meetings and wrote a blueprint. Dr. Al Benson, one of our co-chairs on the project, presented a preview of the blueprint at the 2016 American Association of Cancer Research (AACR) Meeting.
The momentum built for our work.
In September 2017, the blueprint was accepted for publication by the Cancer Immunology Research Journal and published in its November 2017 issue.
Learn more about how we fund colorectal cancer research directly.